12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
-
Publication number: 20130036481Abstract: The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of A? peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.Type: ApplicationFiled: January 6, 2011Publication date: February 7, 2013Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Gregory J. Bix, Sarah Wright, Irene Griswold-Prenner
-
Publication number: 20130035291Abstract: The present invention relates to the production of bioactive products from raw plant matter, namely cocoa extracts. The said products have one or more biopeptides with prolyl endopeptidase (PEP) enzyme inhibitory activity in vitro and/or antioxidant and/or antineurodegenerative capacity in vivo and can be used in dietetics and in the food and pharmaceutical industries.Type: ApplicationFiled: December 23, 2009Publication date: February 7, 2013Applicants: NATRACEUTICAL INDUSTRIAL S.L.U., BIOPOLIS, S.L.Inventors: Esther Bataller Leiva, Salvador Genoves Martinez, Patricia Martorell Guerola, Daniel Ramon Vidal, Aida Ibañnez Lopez, Silvia Llopis Pla, Nuria Gonzalez Martinez, Honorato Monzo Oltra, Begoña Muguerza Marquinez
-
Patent number: 8367800Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: September 6, 2011Date of Patent: February 5, 2013Assignee: Synergy Pharmaceuticals Inc.Inventor: Kunwar Shailubhai
-
Patent number: 8367799Abstract: According to the present invention, peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 9, 23, 25, 30, 60, 63 or 68 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from the group of SEQ ID NOs: 3, 4, 9, 23, 25, 30, 60, 63 and 68. The peptide can include one, two, or several amino acid substitutions or addition so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for treating and/or prophylaxis of tumors, and/or prevention of postoperative recurrence thereof, which comprises any of these peptides. The pharmaceutical agents of this invention include vaccines.Type: GrantFiled: April 10, 2008Date of Patent: February 5, 2013Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa
-
Patent number: 8367620Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.Type: GrantFiled: February 28, 2007Date of Patent: February 5, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
-
Publication number: 20130029903Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the HIV-1 retrovirus.Type: ApplicationFiled: January 3, 2012Publication date: January 31, 2013Inventors: Piotr P. Ruchala, Robert I. Lehrer
-
Publication number: 20130029902Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.Type: ApplicationFiled: July 3, 2008Publication date: January 31, 2013Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Publication number: 20130029920Abstract: A metal nanoparticle-phosphopeptide complex comprising a metal nanoparticle and a phosphopeptide is provided. The phosphopeptide comprises two or more contiguous peptide motifs and two or more phosphorus-containing groups capable of interacting with the surface of the metal nanoparticle. The amino acids at the equivalent position in each peptide motif have similar structural and/or electronic properties. Each phosphorus-containing group is bound to an amino acid in the two or more contiguous peptide motifs. Methods for preparing the metal nanoparticle-phosphopeptide complex are also provided.Type: ApplicationFiled: July 30, 2012Publication date: January 31, 2013Inventors: Margaret A. Brimble, Stefanie Papst, Raoul Peltier, Richard D. Tilley, David E. Williams
-
Publication number: 20130029921Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.Type: ApplicationFiled: April 8, 2011Publication date: January 31, 2013Inventors: Sebastien Gibot, Marc Derive
-
Patent number: 8357775Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: May 9, 2012Date of Patent: January 22, 2013Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Publication number: 20130018003Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: September 17, 2012Publication date: January 17, 2013Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Patent number: 8354380Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.Type: GrantFiled: June 17, 2005Date of Patent: January 15, 2013Assignee: MannKind CorporationInventors: Liping Liu, Adrian Bot, David C. Diamond
-
Patent number: 8354246Abstract: The invention provides a method of inhibiting a bacterial RNA polymerases. The invention has applications in control of bacterial RNA polymerase activity, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.Type: GrantFiled: December 18, 2009Date of Patent: January 15, 2013Assignee: Rutgers, The State University of New JerseyInventors: Richard H. Ebright, Jayanta Mukhopadhyay, Konstantin Severinov, Ekaterina Semenova
-
Patent number: 8354379Abstract: The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides.Type: GrantFiled: August 14, 2007Date of Patent: January 15, 2013Assignee: University of MiamiInventor: Richard L. Rotundo
-
Publication number: 20130012451Abstract: The invention provides peptides, portions and derivatives thereof, that are useful for reducing cell migration, and for reducing symptoms of pathological diseases that are associated with undersirable cell migration, and in particular MMP-9-induced cell migration.Type: ApplicationFiled: December 20, 2010Publication date: January 10, 2013Inventors: Jian Cao, Antoine Dufour
-
Publication number: 20130012456Abstract: Compositions and methods are provided including a peptide derived from the loop2 domain of the lynx1 protein for transport to a target inside the blood brain barrier.Type: ApplicationFiled: June 3, 2012Publication date: January 10, 2013Inventor: Andreas Walz
-
Patent number: 8349804Abstract: The present invention relates to a pharmaceutical composition comprising a bone graft material, a scaffold for tissue engineering applications and type I collagen Binding Peptides which have bone calcification-promoting peptides immobilized on the surface, and more particularly, to a bone graft material and a scaffold for tissue engineering applications (hereinafter, referred to as scaffold), which have peptides specifically binding with type I collagen immobilized on the surface, and pharmaceutical composition for recovering tissue regeneration containing type I collagen binding-inducing peptide.Type: GrantFiled: January 19, 2007Date of Patent: January 8, 2013Assignee: Seoul National University Industry FoundationInventors: Yoon-Jeong Park, Chong-Pyoung Chung, Seung-Jin Lee, Jue-Yeon Lee
-
Patent number: 8349802Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).Type: GrantFiled: August 29, 2011Date of Patent: January 8, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20120321609Abstract: A method of desensitizing 5-HT2R signaling in the mammal is provided. The method comprises one or more of: 1) inhibiting CRFR1 activation of 5-HT2AR signaling by preventing trafficking of intracellular vesicles or blocking recycling of 5-HT2AR to the cell surface; 2) blocking PDZ binding motifs in the carboxyl-terminal tail domains of at least one of CRFR1, 5-HT2AR or 5-HT2CR; or 3) blocking the interaction of a 5-HT2R or a CRFR1 with a PDZ-domain-containing protein selected from the group consisting of MAGI-1 PDZ1, MAGI-2 PDZ1, MAGI-3 PDZ1, PSD95 PDZ 1&2, PSD95 PDZ3, CAL PDZ, SAP97 PDZ 1&2, PTPN13 PDZ 4&5, PDZK2 PDZ1, MPP3 PDZ, ERBIN PDZ and MUPP1 PDZ 12.Type: ApplicationFiled: April 11, 2012Publication date: December 20, 2012Inventors: Stephen Ferguson, Ana Magalhaes, Hymie Anisman
-
Patent number: 8334259Abstract: Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.Type: GrantFiled: September 21, 2007Date of Patent: December 18, 2012Assignees: The Board of Regents, The University of Texas System, The Texas A&M University SystemInventors: Darrell H. Carney, Barbara Olszewska-Pazdrak, Theresa W. Fossum
-
Patent number: 8329144Abstract: A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.Type: GrantFiled: November 3, 2006Date of Patent: December 11, 2012Assignee: Isis Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Publication number: 20120308513Abstract: The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Applicant: Dendreon CorporationInventors: Jami B. Wollan, Lori A. Jones
-
Publication number: 20120309695Abstract: The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.Type: ApplicationFiled: August 15, 2012Publication date: December 6, 2012Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Ritesh Sanghvi, Andreas Grill, Rahul Surana, Hiajian Zhu
-
Publication number: 20120309675Abstract: Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the prophylaxis or therapy of ischemic diseases.Type: ApplicationFiled: June 1, 2012Publication date: December 6, 2012Applicant: CHONNAM NATIONAL UNIVERSITY HOSPITALInventors: Taek Rim YOON, Hyung Keun KIM, Ji Hyun KIM
-
Patent number: 8324170Abstract: A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFN?R2.Type: GrantFiled: August 9, 2010Date of Patent: December 4, 2012Assignee: Case Western Reserve UniversityInventor: Shigemi Matsuyama
-
Patent number: 8324344Abstract: Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition.Type: GrantFiled: October 7, 2009Date of Patent: December 4, 2012Assignee: STC.UNMInventor: Walter Kisiel
-
Patent number: 8314065Abstract: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.Type: GrantFiled: April 21, 2010Date of Patent: November 20, 2012Inventor: Abburi Ramaiah
-
Publication number: 20120289460Abstract: This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.Type: ApplicationFiled: December 3, 2010Publication date: November 15, 2012Applicant: SYNERGY PHARMACEUTICALS INC.Inventor: Kunwar Shailubhai
-
Publication number: 20120282196Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: May 14, 2012Publication date: November 8, 2012Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20120283182Abstract: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and therefore all peptides shown in the Figures of this application (combined with the HIV-Tat protein transduction, COIV mitochondrial targeting and Flag domains) are included for their efficacies in these conditions.Type: ApplicationFiled: February 21, 2012Publication date: November 8, 2012Inventors: John A. Johnson, Tiffany Tuyen M. Nguyen, Mourad Ogbi
-
Publication number: 20120276107Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.Type: ApplicationFiled: December 29, 2011Publication date: November 1, 2012Inventors: Joel Barry Baseman, Thirumalai Regasamy Kannan
-
Publication number: 20120277166Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.Type: ApplicationFiled: May 25, 2011Publication date: November 1, 2012Applicant: XENOME LIMITEDInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
-
Publication number: 20120277158Abstract: The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.Type: ApplicationFiled: October 5, 2010Publication date: November 1, 2012Applicant: Angiochem Inc.Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Anthony Regina
-
Patent number: 8299032Abstract: A self-assembling peptide containing a polar amino acid residue and a nonpolar amino acid residue, wherein the self-assembling peptide contains an acidic amino acid residue and a basic amino acid residue as the polar amino acid residues, a total sum of charge of the acidic amino acid residue and charge of the basic amino acid residue in a neutral region is the number excluding 0, and the self-assembling peptide is capable of forming a beta (?)-sheet structure in which only the nonpolar amino acid residue is arranged on one face upon self-assembly in an aqueous solution.Type: GrantFiled: June 26, 2006Date of Patent: October 30, 2012Assignee: Menicon Co., Ltd.Inventors: Hidenori Yokoi, Takatoshi Kinoshita
-
Patent number: 8299027Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: GrantFiled: September 17, 2010Date of Patent: October 30, 2012Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Patent number: 8299023Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2??(I) (SEQ ID NO: 1), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: GrantFiled: August 25, 2009Date of Patent: October 30, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Waleed Danho, David Charles Fry, Robert Alan Goodnow, Jr., Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
-
Publication number: 20120270811Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.Type: ApplicationFiled: October 21, 2011Publication date: October 25, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
-
Publication number: 20120270808Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.Type: ApplicationFiled: April 4, 2012Publication date: October 25, 2012Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
-
Publication number: 20120270795Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: January 26, 2010Publication date: October 25, 2012Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
-
Publication number: 20120269829Abstract: Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.Type: ApplicationFiled: October 15, 2010Publication date: October 25, 2012Inventors: Yu Tian Wang, Shu Zhang, Changiz Taghibiglou
-
Publication number: 20120264682Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: ApplicationFiled: April 16, 2012Publication date: October 18, 2012Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony CERAMI, Michael Brines, Thomas Coleman
-
Publication number: 20120264685Abstract: The present invention provides novel short chain peptidomimetics, which act as GLP-1 receptors agonist and glucagon receptor antagonist. These dual acting peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme, GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, these short chain peptidomimetics can be delivered by oral routes of administration, for the treatment or prevention of diabetes and related metabolic disorders, such as obesity, hyperlipidemia and eating disorders.Type: ApplicationFiled: October 18, 2010Publication date: October 18, 2012Inventors: Rajesh Bahekar, Mukul R. Jain, Pankaj R. Patel
-
Patent number: 8288351Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8288334Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing.Type: GrantFiled: June 14, 2010Date of Patent: October 16, 2012Assignee: Gene Signal International SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20120258921Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing.Type: ApplicationFiled: April 5, 2012Publication date: October 11, 2012Applicant: 13Therapeutics, Inc.Inventors: Sharon L. McCoy, Steven H. Hefeneider
-
Patent number: 8283311Abstract: A safe and widely-applicable food intake regulator can be provided by using at least one peptide selected from the group consisting of a fish or mammalian melanin-concentrating hormone (MCH) and enzymatic digests thereof, which have the activity to suppress food intake.Type: GrantFiled: March 3, 2009Date of Patent: October 9, 2012Assignee: Maruha Nichiro Foods, Inc.Inventors: Hiroyuki Enari, Motohiko Tada, Yoshinori Takahashi, Masataka Kawarasaki
-
Publication number: 20120252731Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: ApplicationFiled: June 10, 2010Publication date: October 4, 2012Applicant: NoNo, Inc.Inventors: Michael Tymianksi, Jonathan David Garman
-
Patent number: 8278280Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 2, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Publication number: 20120244136Abstract: The present invention relates to Cardiac Targeting Peptides or CTPs that are able to transduce cardiomyocytes specifically in culture and in vivo, and to methods for using such peptides and their derivatives to deliver peptides, proteins or nucleic acids specifically to the heart. It is based, at least in part, on the discovery that the peptide APWHLSSQYSRT (SEQ ID NO:1) functioned as a cardiac-specific protein targeting peptide and was successful in delivering a number of different cargoes to cardiac muscle cells in vitro and in vivo.Type: ApplicationFiled: October 14, 2011Publication date: September 27, 2012Inventors: Paul David Robbins, Maliha Zahid
-
Publication number: 20120245091Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: ApplicationFiled: August 24, 2010Publication date: September 27, 2012Applicant: SUPADELIXIR INC.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju